Sensei Biotherapeutics to host KOL webinar on “Lessons from VISTA”

Sensei Biotherapeutics announced that the company will host a key opinion leader webinar, "Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint," on Monday, November 21, 2022 at 2:15 p.m. ET. The webinar will feature Robert Schreiber, Ph.D., Andrew M. and Jane M. Distinguished Professor of Pathology and Immunology at the Washington University School of Medicine, and member, Sensei Bio Immuno-oncology Advisory Board, who will provide background on VISTA, discuss the unmet medical needs present in the current immuno-oncology treatment landscape and present on the importance of VISTA in developing highly selective therapeutics. Sensei management will also provide an overview of its lead program SNS-101, a conditionally active, pH-sensitive VISTA-blocking antibody, including a review of preclinical data. SNS-101 is being developed to selectively block the VISTA checkpoint within a low-pH tumor microenvironment.